MX2020002075A - Administración en bolo múltiple de [6r]-mthf en quimioterapia basada en 5-fluorouracilo. - Google Patents
Administración en bolo múltiple de [6r]-mthf en quimioterapia basada en 5-fluorouracilo.Info
- Publication number
- MX2020002075A MX2020002075A MX2020002075A MX2020002075A MX2020002075A MX 2020002075 A MX2020002075 A MX 2020002075A MX 2020002075 A MX2020002075 A MX 2020002075A MX 2020002075 A MX2020002075 A MX 2020002075A MX 2020002075 A MX2020002075 A MX 2020002075A
- Authority
- MX
- Mexico
- Prior art keywords
- fluorouracil
- mthf
- bolus administration
- based chemotherapy
- multiple bolus
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187682.4A EP3446703A1 (en) | 2017-08-24 | 2017-08-24 | 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy |
| PCT/EP2018/050274 WO2019037899A1 (en) | 2017-08-24 | 2018-01-05 | ADMINISTRATION OF MULTIPLE [6R] -MTHF BOLUSES DURING CHEMOTHERAPY BASED ON 5-FLUORO-URACILE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002075A true MX2020002075A (es) | 2020-08-13 |
Family
ID=59702572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002075A MX2020002075A (es) | 2017-08-24 | 2018-01-05 | Administración en bolo múltiple de [6r]-mthf en quimioterapia basada en 5-fluorouracilo. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10328079B2 (https=) |
| EP (4) | EP3446703A1 (https=) |
| JP (3) | JP2020531492A (https=) |
| KR (1) | KR102227451B1 (https=) |
| CN (1) | CN110214023A (https=) |
| AU (1) | AU2018319671A1 (https=) |
| BR (1) | BR112020003604A2 (https=) |
| CA (2) | CA3073608C (https=) |
| DK (1) | DK3446706T3 (https=) |
| ES (1) | ES2889573T3 (https=) |
| HU (1) | HUE056275T2 (https=) |
| IL (1) | IL272876B (https=) |
| MX (1) | MX2020002075A (https=) |
| PL (1) | PL3446706T3 (https=) |
| PT (1) | PT3446706T (https=) |
| RU (1) | RU2762596C2 (https=) |
| SG (2) | SG11202001371YA (https=) |
| TW (1) | TWI772354B (https=) |
| WO (1) | WO2019037899A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| US10292984B2 (en) | 2017-02-14 | 2019-05-21 | Isofol Medical Ab | Methods for increasing blood plasma 2′-deoxyuridine (dUrd) and thymidylate synthase inhibition |
| WO2023046305A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer |
| WO2023046304A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer |
| WO2023046307A1 (en) * | 2021-09-27 | 2023-03-30 | Isofol Medical Ab | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer |
| US20240350495A1 (en) * | 2023-04-20 | 2024-10-24 | Isofol Medical Ab | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of carcinoma |
| EP4450071A1 (en) | 2023-04-20 | 2024-10-23 | Isofol Medical AB | [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer |
| EP4534088A1 (en) | 2023-10-04 | 2025-04-09 | Isofol Medical AB | Arfolitixorin for use in vitamin b6-enhanced, 5-fluorouracil-based chemotherapy of carcinomas |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376658A (en) * | 1990-05-11 | 1994-12-27 | University Of Southern California | 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CN1942189A (zh) * | 2004-04-02 | 2007-04-04 | 阿德文特克斯药物有限公司 | 5,10－亚甲基四氢叶酸在癌症治疗中的用途 |
| JP2007531728A (ja) * | 2004-04-02 | 2007-11-08 | アドベントルクス ファーマシューティカルズ， インコーポレイテッド | 癌の処置のための５，１０−メチレンテトラヒドロ葉酸の使用 |
| EP1968551A2 (en) * | 2005-12-02 | 2008-09-17 | Adventrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate |
| WO2008109349A1 (en) | 2007-03-06 | 2008-09-12 | Adventrx Pharmaceuticals, Inc. | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine |
| EP2617421A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer |
| EP2837631A1 (en) * | 2013-08-14 | 2015-02-18 | Merck & Cie | New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid |
| EP3305318A1 (en) | 2016-10-05 | 2018-04-11 | Isofol Medical AB | [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy |
-
2017
- 2017-08-24 EP EP17187682.4A patent/EP3446703A1/en not_active Withdrawn
-
2018
- 2018-01-05 EP EP21161447.4A patent/EP3854399A1/en not_active Withdrawn
- 2018-01-05 EP EP18700858.6A patent/EP3672624A1/en not_active Withdrawn
- 2018-01-05 CN CN201880008869.7A patent/CN110214023A/zh active Pending
- 2018-01-05 PL PL18150457T patent/PL3446706T3/pl unknown
- 2018-01-05 AU AU2018319671A patent/AU2018319671A1/en not_active Abandoned
- 2018-01-05 EP EP18150457.2A patent/EP3446706B1/en active Active
- 2018-01-05 SG SG11202001371YA patent/SG11202001371YA/en unknown
- 2018-01-05 CA CA3073608A patent/CA3073608C/en active Active
- 2018-01-05 MX MX2020002075A patent/MX2020002075A/es unknown
- 2018-01-05 DK DK18150457.2T patent/DK3446706T3/da active
- 2018-01-05 HU HUE18150457A patent/HUE056275T2/hu unknown
- 2018-01-05 ES ES18150457T patent/ES2889573T3/es active Active
- 2018-01-05 WO PCT/EP2018/050274 patent/WO2019037899A1/en not_active Ceased
- 2018-01-05 BR BR112020003604-8A patent/BR112020003604A2/pt not_active IP Right Cessation
- 2018-01-05 PT PT181504572T patent/PT3446706T/pt unknown
- 2018-01-05 RU RU2020109122A patent/RU2762596C2/ru active
- 2018-01-05 JP JP2020510531A patent/JP2020531492A/ja active Pending
- 2018-01-09 TW TW107100835A patent/TWI772354B/zh not_active IP Right Cessation
- 2018-01-09 US US15/865,847 patent/US10328079B2/en active Active
- 2018-01-09 CA CA2991361A patent/CA2991361A1/en not_active Abandoned
- 2018-01-09 KR KR1020180002961A patent/KR102227451B1/ko not_active Expired - Fee Related
- 2018-01-09 SG SG10201800203SA patent/SG10201800203SA/en unknown
- 2018-02-08 JP JP2018020939A patent/JP6734308B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-04 US US16/240,474 patent/US20190212341A1/en not_active Abandoned
-
2020
- 2020-02-24 IL IL272876A patent/IL272876B/en unknown
- 2020-07-09 JP JP2020118218A patent/JP2020169208A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002075A (es) | Administración en bolo múltiple de [6r]-mthf en quimioterapia basada en 5-fluorouracilo. | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| MX2020002053A (es) | [6r]-mthf - una alternativa eficaz al folato en quimioterapia basada en 5-fluorouracilo. | |
| ES3060467T3 (en) | Anti-pd-l1/pd-1 combinations for treating tumors | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
| PH12017502002A1 (en) | 5`-substituted nucleoside analogs | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
| NZ726732A (en) | Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1’,2’:4,5] pyrazino [2,1-b] [1,3] oxazepine-10-carboxamide | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2015017556A (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos. | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| MX2018004177A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| MX386680B (es) | Polimorfo de macrociclo de diarilo. | |
| MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
| MY192081A (en) | Cancer treatments | |
| EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| BR112018074972A2 (pt) | derivados de adenosina para uso no tratamento de câncer | |
| MX2019003235A (es) | Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4. | |
| WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer |